No abstract

Epidermolysis bullosa acquisita (EBA) is a chronic autoimmune subepidermal bullous disease with clinical features similar to the genetic form of dystrophic epidermolysis bullosa. EBA is characterized by the presence of autoantibodies against type VII collagen which is a major component of the anchoring fibrils at the dermal-epidermal junction. EBA can be divided into two main clinical types; mechanobullous and inflammatory EBA. Mechanobullous EBA, referred to as classic EBA, presents with skin fragility, blisters and dystrophic changes on trauma-prone areas. Inflammatory EBA resembles other autoimmune subepidermal bullous diseases. Compelling evidence from mouse models supports a pathogenic role of autoantibodies against type VII collagen in EBA. Treatment of EBA is often unsatisfactory. The most widely used systemic treatment is corticosteroids. Colchicine and dapsone have been reported to be good treatment modalities when combined with corticosteroids. Some intractable cases of EBA have successfully been treated with intravenous immunoglobulin or rituximab.

Amid the pandemic crisis, patient-reported health behaviours are of high translational value, as essential components of appraising preventative care. Our results demonstrate that COVID-19 vaccine acceptance among patients with psoriasis seems to be driven by heightened risk perception and health awareness, mostly in younger people and highly educated individuals. Nevertheless, our findings should be interpreted with caution, as our study is limited to a single centre.In conclusion, a strong emphasis on the provision of evidence-based information to patients with psoriasis is needed. Factors influencing patients' decision to receive the vaccine and individual features of subpopulations should be considered whenever COVID-19 immunizati/tcgqaon strategies are designed by policymakers and national health systems.